Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

Parul Ichhpujani1,2
L Jay Katz1
1William and Anna Goldberg Glaucoma Service, Wills Eye Institute, Philadelphia, PA, USA;
2Department of Ophthalmology, Government Medical College and Hospital, Chandigrah, India

Abstract: Combination pharmacotherapy has simplified and improved glaucoma medication regimens. This update focuses on the previous and recent studies on efficacy and tolerability profile of dorzolamide–timolol in adult ocular hypertension and open angle glaucoma patients. Dorzolamide–timolol has been shown to be efficacious and well tolerated in clinical trials and the adverse effects reflect those of the individual components.

Keywords: glaucoma, ocular hypertension, dorzolamide, timolol

Introduction

Glaucoma is a worldwide epidemiological challenge affecting approximately 4% of the global population.1–7 Research shows that by 2010, an estimated 60.5 million people globally will be living with either angle closure glaucoma (ACG) or primary open angle glaucoma (POAG).8 Elevated intraocular pressure is the most important modifiable risk factor for glaucoma and hence lowering of IOP is the goal of glaucoma therapy.9,10 Pharmacotherapy remains the chief management modality for the patients of glaucoma and ocular hypertension.9 Topical antiglaucoma medications act either by decreasing aqueous production (beta adrenergic antagonists, carbonic anhydrase inhibitors [CAI]) or increasing aqueous outflow (prostaglandin derivatives, cholinergic agonists) or both (alpha-2 adrenergic agonists).9 Treatment is started with monotherapy but in cases where monotherapy fails to attain the target IOP, other drugs are added.9,10 Factors that influence the choice of an agent are efficacy, safety profile, ease of administration and cost.11,12 Fixed drug combinations can help to avoid complex dosing schedules of multi drug glaucoma therapy and thus improve compliance.12,13 Several fixed combinations of commonly used IOP-lowering medications have been developed and are available in various markets worldwide. Most fixed combinations contain timolol, as it can be dosed either once or twice daily and can be combined with prostaglandin analogs, adrenergic agonists, and CAIs.13 Cosopt® (Merck & Co., Inc., Whitehouse Station, NJ, USA), a commonly available combination drug that consists of dorzolamide hydrochloride 2% and timolol maleate 0.5% was first commercially introduced in 1998. Each milliliter of Cosopt consists of 22.26 mg dorzolamide hydrochloride and 6.83 mg timolol maleate with 0.0075% benzalkonium chloride as preservative.14 This update focuses on the previous and recent studies on efficacy and tolerability profile of dorzolamide–timolol in adult ocular hypertension and open angle glaucoma patients.
Mode of action, pharmacodynamic and pharmacokinetic profile

The pharmacodynamic properties of timolol and dorzolamide have been extensively reviewed elsewhere. There is no direct pharmacodynamic interaction between the two drugs, a brief overview of the pharmacodynamic and pharmacokinetic profile of each drug is presented here.

Timolol is a non-selective β-blocker (β1 and β2) which has little or no local anesthetic, membrane stabilizing or sympathomimetic properties. Timolol lowers IOP by inhibiting aqueous humor production and it has been suggested that timolol down-regulates adenylate cyclase by inhibiting β2-adrenoceptor sites at the ciliary process. Dorzolamide is a highly selective inhibitor of CA-II, an isoenzyme present on the ciliary process in the eye. Inhibition of CA-II slows local bicarbonate production, decreases sodium and fluid transport and, consequently, decreases aqueous humor production and lowers IOP. Because their mechanisms of action differ, they have an additive effect when administered together.

Approximately 80% of the volume of topically administered eye drops is absorbed systemically within 15 to 30 seconds of instillation. Chronic administration of dorzolamide leads to its accumulation in erythrocytes. Hepatic metabolism of dorzolamide produces N-desethyl metabolite which also binds to red blood cells but inhibits carbonic anhydrase I more than carbonic anhydrase II. Approximately 24% to 32% of systemically absorbed dorzolamide is bound to plasma proteins.

Urine is the major route of excretion for both parent and metabolite drug. There is a rapid decline of dorzolamide from red blood cells, on discontinuation of the medication. This is followed by a gradual decline due to an elimination phase half-life of approximately 4 months. However, in patients with glaucoma treated with dorzolamide 2% 3 times daily, plasma concentrations after 12 months were similar to those after 6 months (20 µmol/L). Because of its renal elimination, dorzolamide eyedrops are not recommended in patients with severe renal impairment. Topical dorzolamide has not been studied in patients with hepatic dysfunction, but should be used with caution as the drug undergoes hepatic metabolism.

Not much has been published on the pharmacokinetic characteristics of fixed combination of dorzolamide and timolol, accordingly the characteristics of individual components are being discussed.

Topical dorzolamide is absorbed through nasopharyngeal mucosa into systemic circulation. Biollaz et al have shown that plasma concentration of dorzolamide remained below level of detection after instillation of single or multiple doses of dorzolamide 2 or 3% in healthy volunteers. Dorzolamide undergoes slow metabolism by cytochrome P450 (CYP) 2B1/2, CYP2E1 and CYP3A2.

CAIs have been reported to improve ocular blood flow profile by causing ocular vasodilation through metabolic acidosis via elevated carbon dioxide levels. Topically administered dorzolamide–timolol has been shown to improve some markers of ocular blood flow in small studies (n = 15–30) in patients with POAG. Retinal arteriovenous time passage time from superior temporal artery to the corresponding vein was significantly shorter following 1 month of double masked treatment with dorzolamide–timolol twice daily than with timolol 0.5% twice daily (P = 0.01). The fixed combination did not alter choroidal perfusion or retrobulbar hemodynamics relative to timolol 0.5% baseline in this randomized crossover comparison (n = 15). However, this finding contrasts with that of a crossover comparison of latanoprost 0.005% in which 1 month of non-blind treatment with dorzolamide–timolol significantly (P = 0.003) increased pulsatile ocular blood flow by 2.05 µL/s relative to the timolol 0.5% baseline. Dorzolamide–timolol also significantly improved retrobulbar hemodynamic parameters relative to baseline in another randomized cross over comparative study with latanoprost. The fixed combination increased end diastolic velocity and decreased the resistance index in both the ophthalmic artery and short posterior ciliary artery. Improvements in ocular blood flow markers following treatment with dorzolamide 2%/timolol 0.5% generally exceeded those observed with latanoprost 0.005% once daily in 2 cross over randomized studies.

A recent study has shown dorzolamide 2%/timolol 0.5% fixed combination increased blood flow significantly at the neuroretinal rim showing a combination of hypotensive and hemodynamic effects. Twenty-eight patients with early-moderate glaucomatous damage treated with beta-blockers (>6 months) with IOP values ranging from 18 to 22 mmHg at trough participated in this trial. After a 4-week washout period, patients were randomized in two groups: group I started with dorzolamide 2% monotherapy and group II with timolol 0.5% monotherapy for 4 weeks. After this period, both groups switched to dorzolamide 2%/timolol 0.5% fixed combination for 4 weeks. IOP, ocular diastolic perfusion pressure (ODPP), heart rate, and Scanning Laser Doppler Flowmetry measurements at the peripapillary retina and neuroretinal rim were taken at T0 (enrolment), T1 (wash out), T2 (monotherapy), and T3 (dorzolamide–timolol). Between T1 and T3, IOP decreased significantly in group I (21.40%).
(P < 0.001) and in group II (−21.25%) (P < 0.001). At the same time intervals, blood flow increased significantly at rim level for group I (+30.03%) (P < 0.05) and also when all patients were considered (rim +17.99%) (P < 0.05). Between T1 and T3, there was a significant increase of ODPP in group I (+7.24%) (P < 0.01) and in group II (+6.08%) (P < 0.05) and when all patients were considered (+8.43%) (P < 0.01).36

The improvement in ocular blood flow parameters with the fixed combination appears to reflect the activity of the dorzolamide 2% component. When included as a comparator, timolol 0.5% had no significant effect on ocular blood flow markers in these studies.31,37,38 However these improved ocular blood flow parameters were not accompanied by any enhancement in visual function.35,37

Dosage and administration
Dorzolamide 2%/timolol 0.5% is indicated for the treatment of raised IOP in patients with ocular hypertension, open-angle glaucoma, pseudoxfoliative glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate. It may be used along with prostaglandin analogs when IOP control is not possible with a single medication. It can also be used when prostaglandin analogs cannot be used such as, if patient has a history of herpetic keratitis or is concerned about side effects like iris heterochromia and periocular pigmentation.

Dorzolamide/timolol should be used with caution in those with hepatic insufficiency and is not recommended in patients with severe renal impairment (creatinine clearance <1.8 L/h [<30 mL/min]). It is contraindicated in Europe in patients with hypercholesteremic acidosis. Dorzolamide/timolol is contraindicated in patients with a history of bronchial asthma, severe obstructive pulmonary disease, cardiac failure, sinus bradycardia, atrioventricular block or cardiogenic shock. Finally, the formulation should not be used in patients with known hypersensitivity to either of the components (eg, sensitivity to sulfonamides).

Therapeutic efficacy
The fixed combination dorzolamide–timolol has been compared with monotherapy dorzolamide 2%,39,40 timolol 0.5%,39,40 latanoprost 0.005%,41–48 bimatoprost 0.03%,39,50 travoprost 0.004%,37,48,51 unoprostone 0.15%52 and with concomitant therapy with dorzolamide 2% and timolol 0.5%,53,54 brimonidine 0.2% plus either timolol 0.5%55–58 or latanoprost 0.005%59 and pilocarpine 2% with timolol 0.5%.60,61 Recently, it has also been compared with fixed combination latanoprost 0.005%/timolol 0.5%,62–64 brinzolamide 1%/timolol 0.5%65,66 and travoprost 0.004%/timolol 0.5%67 in randomized clinical trials carried out at various centers across the world. Another recent study reports the additive effect of dorzolamide 2%/timolol 0.5% fixed combination in patients under monotherapy with latanoprost.68

Adults with POAG or ocular hypertension who did not have any contraindications for the study medications were enrolled in these trials. Based on the available demographic details, the mean or the median age of trial participants ranged from 58.5 to 66.5 years. The subjects were recruited if they had a baseline morning trough and/or morning peak IOP of ≥ 20 mmHg, after completing a 2- to 6-week run in period on timolol 0.5% twice daily or a washout period of 3 to 28 days (depending on drug class).

In most studies the primary efficacy endpoint was the mean change in IOP from time-matched baseline values, the mean change in diurnal IOP from baseline or the between group difference in the mean reduction in daytime diurnal IOP from baseline.

Versus concomitant or monotherapy
The efficacy of dorzolamide 2%/timolol 0.5% compared with mono or concomitant therapy with the same drugs has been evaluated in 4 major clinical studies involving a total of 1129 patients with glaucoma.39,40,53,54 (Table 1). All studies were multicenter, randomized, parallel and double-blind with active controls. Many patients enrolled in these trials were previously using one or the other antiglaucoma medications.39,40,54 To establish a comparable baseline, patients underwent a 2-,3,5,40 or 3-week40 run-in period on timolol 0.5% twice daily, or a washout period of 3 to 21 days depending on the medication.39 Where dorzolamide 2%/timolol 0.5% was compared with timolol 0.5% or dorzolamide 2% monotherapy, the hypothesis tested was that there was 95% confidence that mean IOP in the combined therapy group differed from that in the monotherapy groups by ≥6%40 or 8%.39 Only 1 trial reported p values for treatment comparisons.40 The controlled study period was 90 days in all trials, with a 9-month open-label extension in 1 trial.34 The age at entry was 21 to 85 years in 3 trials40,53,54 and ≥21 years in 1 trial.39 The IOP at baseline in the worst eye was required to be ≥22 mmHg in 3 of the studies40,53,54 and ≥24 mmHg in 1 study.39 In all studies change in IOP was the primary end-point and was measured at trough (0 hours) and peak (2 hours) in relation to the morning dose of medication 14, 30, 60 and 90 days after

Dovepress
Drug, Healthcare and Patient Safety downloaded from https://www.dovepress.com/ by 54.70.40.11 on 05-Jan-2019
For personal use only.
Table 1  FCDT vs monotherapy or concomitant therapy with dorzolamide and/or timolol

<table>
<thead>
<tr>
<th>Authors</th>
<th>Time point</th>
<th>Treatment</th>
<th>N</th>
<th>Baseline IOP (SD) (mmHg)</th>
<th>Treatment IOP (SD) (mmHg)</th>
<th>Change (SD)</th>
<th>% change (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyle et al49</td>
<td>Month 3 trough</td>
<td>FCDT</td>
<td>114</td>
<td>27.8 (5.0)</td>
<td>20.1 (4.5)</td>
<td>−7.7 (4.2)</td>
<td>−27.4 (13.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorzolamide</td>
<td>109</td>
<td>28.1 (4.7)</td>
<td>23.5 (4.2)</td>
<td>−4.6 (4.3)</td>
<td>−15.5 (13.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timolol</td>
<td>111</td>
<td>27.9 (4.6)</td>
<td>21.5 (4.0)</td>
<td>−6.4 (4.1)</td>
<td>−22.2 (12.5)</td>
</tr>
<tr>
<td></td>
<td>Month 3 peak</td>
<td>FCDT</td>
<td>112</td>
<td>27.1 (4.3)</td>
<td>18.1 (3.8)</td>
<td>−9.0 (4.3)</td>
<td>−32.7 (12.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorzolamide</td>
<td>109</td>
<td>27.3 (3.8)</td>
<td>21.8 (4.3)</td>
<td>−5.4 (3.6)</td>
<td>−19.8 (12.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timolol</td>
<td>110</td>
<td>27.3 (4.4)</td>
<td>21.0 (4.7)</td>
<td>−6.3 (4.7)</td>
<td>−22.6 (15.6)</td>
</tr>
<tr>
<td>Clineschmidt et al49</td>
<td>Month 3 trough</td>
<td>FCDT</td>
<td>102</td>
<td>25.5 (3.4)</td>
<td>22.7 (3.9)</td>
<td>−2.8 (3.4)</td>
<td>−10.6 (12.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorzolamide</td>
<td>51</td>
<td>25.5 (3.8)</td>
<td>24.2 (5.1)</td>
<td>−1.4 (4.3)</td>
<td>−4.9 (16.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timolol</td>
<td>98</td>
<td>25.2 (3.1)</td>
<td>23.6 (4.3)</td>
<td>−1.7 (3.1)</td>
<td>−6.7 (11.9)</td>
</tr>
<tr>
<td></td>
<td>Month 3 peak</td>
<td>FCDT</td>
<td>103</td>
<td>25.0 (3.9)</td>
<td>20.7 (4.5)</td>
<td>−4.4 (3.3)</td>
<td>−17.3 (12.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorzolamide</td>
<td>51</td>
<td>24.7 (3.3)</td>
<td>22.7 (3.8)</td>
<td>−2.0 (4.1)</td>
<td>−7.4 (15.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timolol</td>
<td>95</td>
<td>24.3 (2.6)</td>
<td>22.8 (4.6)</td>
<td>−1.6 (3.7)</td>
<td>−6.6 (15.3)</td>
</tr>
<tr>
<td>Hutzelmann et al41</td>
<td>Month 3</td>
<td>FCDT</td>
<td>151</td>
<td>25.6 (3.1)</td>
<td>21.4 (4.1)</td>
<td>−4.2 (3.3)</td>
<td>−16.3 (12.5)</td>
</tr>
<tr>
<td></td>
<td>Trough</td>
<td>D + T</td>
<td>148</td>
<td>25.3 (3.2)</td>
<td>21.1 (3.7)</td>
<td>−4.2 (3.1)</td>
<td>−16.3 (11.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCDT</td>
<td>151</td>
<td>24.7 (3.2)</td>
<td>19.4 (3.7)</td>
<td>−5.4 (3.1)</td>
<td>−21.6 (12.3)</td>
</tr>
<tr>
<td></td>
<td>Month 3 peak</td>
<td>D + T</td>
<td>148</td>
<td>24.5 (3.2)</td>
<td>19.1 (3.5)</td>
<td>−5.4 (3.3)</td>
<td>−21.8 (11.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCDT</td>
<td>120</td>
<td>26.1 (3.0)</td>
<td>22.5 (4.1)</td>
<td>−3.6 (3.0)</td>
<td>−13.8 (11.1)</td>
</tr>
<tr>
<td>Strohmaier et al44</td>
<td>Month 3</td>
<td>Trough</td>
<td>D + T</td>
<td>121</td>
<td>26.1 (3.8)</td>
<td>22.0 (4.4)</td>
<td>−4.1 (3.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCDT</td>
<td>119</td>
<td>25.1 (3.3)</td>
<td>20.1 (3.8)</td>
<td>−5.0 (3.5)</td>
<td>−19.7 (12.9)</td>
</tr>
<tr>
<td></td>
<td>Month 3 peak</td>
<td>D + T</td>
<td>120</td>
<td>25.0 (3.7)</td>
<td>20.2 (4.2)</td>
<td>−4.9 (3.8)</td>
<td>−19.1 (14.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCDT</td>
<td>116</td>
<td>23.7 (3.9)</td>
<td>20.0 (3.9)</td>
<td>−3.7 (3.4)</td>
<td>−14.9 (13.2)</td>
</tr>
</tbody>
</table>

Abbreviations: FCDT, fixed combination dorzolamide–timolol; D, dorzolamide; T, timolol.

initiation of therapy. In 1 study, an additional measurement was made at 8 hours.53 The concentrations of the individual drugs in both the combined and monotherapy formulations were dorzolamide 2% and timolol 0.5%. In all studies the primary efficacy analyses were based on the last observation carried forward approach, although secondary analyses were performed using other methods in 3 studies.39,40,53 The studies that compared combined and concomitant therapy were designed to determine equivalence and this was assessed by calculating the 90% or 95% confidence interval for the hypothesis that the mean IOP of each of the 2 treatment groups differed by ≤1.5 mmHg.

**Versus prostaglandin analogs**

**Versus latanoprost 0.005%**

Dorzolamide 2%/timolol 0.5% was comparable to latanoprost 0.005% once daily in two double masked comparisons that followed a washout period41 (Table 2). The mean reduction of daytime diurnal IOP between the groups from baseline at 3 months was within ±1.5 mmHg study 1: −0.04 mmHg [95% CI: −0.85, 0.77] in favor of dorzolamide 2%/timolol 0.5%; study 2: −0.57 mmHg [95% CI: 1.31, 0.16] in favor of dorzolamide 2%/timolol 0.5%.

Additional post hoc analyses of pooled data from these trials showed dorzolamide 2%/timolol 0.5% and latanoprost 0.005% were similar with respect to percentages of patients achieving target levels of IOP reduction.49

**Versus bimatoprost 0.03%**

Dorzolamide 2%/timolol 0.5% twice daily lowered IOP less consistently than did bimatoprost 0.03% once daily in a double-masked, parallel-group comparison following a run-in period on timolol 0.5% twice daily.49 Mean reductions in IOP from baseline at morning trough and peak were greater with bimatoprost 0.03% at all time points, with the exception of the morning peak time point at 3 months."
Combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

provided a less stable reduction in IOP over the whole day, as evidenced by significantly lower mean IOP values in bimatoprost 0.03% recipients at the 0-, 8- and 12-hour post-dose time points at 3 months ($P \leq 0.038$). The percentage of recipients reaching target IOPs of 17 to 20 mmHg was similar between the dorzolamide 2%/timolol 0.5% and bimatoprost 0.03% treatment groups based on measurements at 0-, 2- and 12-hour post-dose time points at 3 months; however, a significantly ($P < 0.008$) greater percentage of bimatoprost 0.03% recipients reached the lower target pressures: $\leq 13$ mmHg (0% vs 8%), $\leq 14$ mmHg (2% vs 17%), $\leq 15$ mmHg (9% vs 24%) and $\leq 16$ mmHg (14% vs 31%).

A relevant concern with this study is whether the selection of patients who are inadequately controlled on timolol 0.5% twice daily provides a valid basis on which to judge the relative merits of a timolol-containing therapy versus bimatoprost 0.03%. Moreover, the study authors did not conduct a reverse therapeutic trial and hence did not know the number of trial participants who were non-responders to timolol. Contrasting with the results of this trial, reductions in day time diurnal IOP (0800–1600 hours) and IOP at 2 of the 3 measured timepoints (morning peak and 8 hours post-dose) were not significantly different with dorzolamide 2%/timolol 0.5% twice daily vs. bimatoprost 0.03% once daily in a small ($n = 35$), double-masked, cross-over, 3-center, 8-week study that followed an initial washout period.

### Versus travoprost 0.004%

The IOP-lowering effect of dorzolamide 2%/timolol 0.5% twice daily was greater than that of travoprost 0.004% once daily in one of two small ($n = 50$ and $n = 56$), single-blind, parallel-group, single-center studies that followed a washout period. After 6 months of treatment, the reduction in mean diurnal IOP (average of measurements made at 0800, 1000 and 1600 hours) from baseline with dorzolamide/timolol was superior to that with travoprost 0.004% (11.5 vs 9.3 mmHg; $P < 0.05$). The IOP-lowering effect of dorzolamide 2%/timolol 0.5% was also greater than that of another comparator, latanoprost 0.005% once daily (reduction in mean diurnal IOP from baseline, 8.2 mmHg; $P < 0.05$ vs dorzolamide/timolol); the IOP-lowering effect of the two prostaglandin analogs was similar. Of note, this study exclusively enrolled patients with pseudoexfoliation glaucoma. Dorzolamide 2%/timolol 0.5% was, however, less effective than travoprost 0.004% in the other single dose blind, parallel-group, single-center comparison, and less effective than both travoprost 0.004% and latanoprost 0.005%

### Table 2 FCDT vs other prostaglandin analogs

<table>
<thead>
<tr>
<th>Authors</th>
<th>Time point</th>
<th>Treatment</th>
<th>Mean baseline IOP (SD) (mmHg)</th>
<th>Mean treatment IOP (SD) (mmHg)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orzalesi et al$^{45}$</td>
<td>Month 1</td>
<td>FCDT</td>
<td>22.6 (2.7)</td>
<td>16.9 (1.4)</td>
<td>$&gt;0.05$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latanoprost</td>
<td>22.6 (2.7)</td>
<td>16.7 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Fechtner et al$^{47}$</td>
<td>Month 3 (study 1)</td>
<td>FCDT</td>
<td>26.1</td>
<td>18.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latanoprost</td>
<td>25.6</td>
<td>18.4</td>
<td>$&gt;0.05$</td>
</tr>
<tr>
<td>Konstas et al$^{44}$</td>
<td>Month 2</td>
<td>FCDT</td>
<td>31.2 (6.5)</td>
<td>18.1 (3.0)</td>
<td>0.21</td>
</tr>
<tr>
<td>Konstas et al$^{44}$</td>
<td>Week 6</td>
<td>FCDT</td>
<td>25.8 (1.4)</td>
<td>15.3 (2.0)</td>
<td>0.05</td>
</tr>
<tr>
<td>(pseudoexfoliation patients)</td>
<td>Month 3 (study 2)</td>
<td>FCDT</td>
<td>23.6 (3.3)</td>
<td>17.2 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Susanna et al$^{42}$</td>
<td>Month 2</td>
<td>FCDT</td>
<td>24.7 (2.3)</td>
<td>16.6 (3.0)</td>
<td>$&gt;0.05$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latanoprost</td>
<td>24.7</td>
<td>15.9 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Day et al$^{46}$</td>
<td>Month 2</td>
<td>FCDT</td>
<td>24.8</td>
<td>18.1 (2.8)</td>
<td>0.35</td>
</tr>
<tr>
<td>Ozturk et al$^{46}$</td>
<td>Month 6</td>
<td>FCDT</td>
<td>24.8</td>
<td>17.4 (2.9)</td>
<td></td>
</tr>
<tr>
<td>Coleman$^{49}$</td>
<td>Month 3 (0800 h)</td>
<td>FCDT</td>
<td>24.8 (2.5)</td>
<td>19.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bimatoprost</td>
<td>24.8 (2.5)</td>
<td>18.2</td>
<td>$&lt;0.001$</td>
</tr>
</tbody>
</table>

Abbreviation: FCDT, fixed combination dorzolamide–timolol.
in a small (n = 38), single-blind, cross-over, single-center comparison that followed a run-in period on timolol 0.5% twice daily. In the parallel-group comparison, the reductions in mean diurnal IOP (average of measurements made at 0800, 1200, 1600 and 2000 hours) from baseline were significantly less with dorzolamide 2%/timolol 0.5% than with travoprost 0.004% after both 3 (23.1% vs 32.7%; P < 0.01) and 6 (21.7% vs 30.7%; P < 0.01) weeks of treatment. Similarly, in the cross-over comparison, the decrease in mean diurnal IOP (average of measurements made at 8 am, 10 am and 4 pm) from baseline following 3 months of treatment with dorzolamide 2%/timolol 0.5% (14.3%; P < 0.0001 vs baseline) was significantly less than that with travoprost 0.004% (18.4%; P < 0.0001 vs baseline and dorzolamide 2%/timolol 0.5%) and latanoprost 0.005% (22.1%; P < 0.0001 vs baseline and dorzolamide 2%/timolol 0.5%). Again, the IOP-lowering effect of the two prostaglandin analogs was similar.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Time point</th>
<th>Treatment</th>
<th>Mean baseline IOP (SD) (mmHg)</th>
<th>Mean treatment IOP (SD) (mmHg)</th>
<th>Treatment difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcieri et al⁴⁸</td>
<td>Month 1</td>
<td>FCDT</td>
<td>22.9 (1.6)</td>
<td>15.4 (2.1)</td>
<td>0.4</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCBT</td>
<td>22.9 (1.6)</td>
<td>15.0 (2.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Konstas et al⁴⁹</td>
<td>Month 2</td>
<td>FCDT</td>
<td>20.2 (1.9)</td>
<td>17.0 (2.0)</td>
<td>0.27</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCLT</td>
<td>20.1 (2.0)</td>
<td>17.3 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shin et al⁵¹</td>
<td>Month 3</td>
<td>FCDT</td>
<td>27.5 (3.1)</td>
<td>19.1 (3.3)</td>
<td>0.6</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCLT</td>
<td>27.9 (3.6)</td>
<td>18.5 (2.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalzuny et al⁴⁴</td>
<td>Week 6</td>
<td>FCDT</td>
<td>23.4 (2.3)</td>
<td>18.0 (2.2)</td>
<td>0.6</td>
<td>0.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCPT</td>
<td></td>
<td>17.4 (2.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day et al⁵²</td>
<td>Week 6</td>
<td>FCDT</td>
<td>24.3 (3.0)</td>
<td>20.1 (4.5)</td>
<td>0.55</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>T + U</td>
<td></td>
<td>20.1 (4.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diurnal curve</td>
<td>FCDT</td>
<td>23.4 (3.2)</td>
<td>19.8 (4.1)</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>T + U</td>
<td></td>
<td>19.8 (4.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teus et al⁵⁷</td>
<td>Week 6</td>
<td>FCDT</td>
<td>26.1 (0.18)</td>
<td>17.7 (0.25)</td>
<td>0.55</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tr + T</td>
<td>26 (0.18)</td>
<td>16.6 (0.26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Month 3 (study 1)</td>
<td>FCDT</td>
<td>6.5</td>
<td>25.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zabriskie and Netland⁵⁰</td>
<td>Month 3</td>
<td>B + L</td>
<td>9.0</td>
<td>33.9</td>
<td>0.044</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FCDT</td>
<td>6.6</td>
<td>26.3</td>
<td>0.047</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B + L</td>
<td>9.1</td>
<td>33.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Versus unoprostone 0.15% and timolol 0.5%**

Day et al conducted a prospective multicenter, randomized, double-masked, crossover comparison study and found a similar efficacy and safety between dorzolamide 2%/timolol 0.5% and concomitant use of unoprostone 0.15% and timolol maleate 0.5% (n = 32). After a 4-week run in period on timolol 0.5% twice daily, the patients received one treatment for 6 weeks and then crossed over to the opposite treatment. The authors found comparable IOP reduction for all the time points, for the diurnal curve or in the extended reduction from baseline (Table 3).

**Versus latanoprost 0.005%/timolol 0.5%**

The reduction in daytime diurnal IOP (0800–1600 hours or 0800–2000 hours) with dorzolamide 2%/timolol 0.5% twice daily vs latanoprost 0.005%/timolol 0.5% once daily significantly favored the latter in a large
(n = 253), single-blind, parallel-group trial preceded by a washout period. However, the between-group difference after 3 months’ treatment (primary endpoint) was only 1.0 mmHg (95% CI 0.4, 1.69; P = 0.005) and the clinical relevance of this small difference is questionable. Daytime diurnal IOP was not significantly different following treatment with these two fixed combinations in a small (n = 33) double-masked, cross-over comparison that followed a run-in period on timolol 0.5% twice daily. For other endpoints in these studies, mean reductions in IOP were significantly less with dorzolamide 2%/timolol 0.5% than with latanoprost 0.005%/timolol 0.5% at morning trough (8.1 vs 9.6 mmHg; P = 0.007) and the 8-hour post-dose timepoint (8.3 vs 9.5 mmHg; P = 0.014) after 3 months’ treatment in the larger trial, but not at the corresponding timepoints after 2 months’ treatment in the smaller trial. Conversely, mean IOP values favored dorzolamide 2%/timolol 0.5% over latanoprost 0.005%/timolol 0.5% at morning peak (17.3 vs 17.8 mmHg; P = 0.04) and the 4-hour post dose timepoint (16.7 vs 17.5 mmHg; P = 0.03) after 2 months’ treatment in the smaller comparison, but not at the 4-hour post-dose timepoint after 3 months’ treatment in the larger comparison (18.6 vs. 18.5 mmHg). In the larger trial, consistently fewer dorzolamide 2%/timolol 0.5% than latanoprost 0.005%/timolol 0.5% recipients achieved specific reductions (range ≥5% to ≥40%) in daytime diurnal IOP at 3 months; these between group differences were statistically significant for the ≥15% (92% vs 99%; P < 0.05), ≥20% (80% vs 92%; P ≤ 0.01), ≥25% (66% vs 81%; P ≤ 0.01) and ≥30% (50% vs 67%; P ≤ 0.01) reduction levels (values estimated from a graph) (Table 3).

**Versus brimonidine 0.2%/timolol 0.5%**

Nixon et al presented a pooled data analysis of 2 randomized, investigator-masked, 3-month, parallel-group studies with identical protocols (10 sites) (n = 180). Patients received topical brimonidine 0.2%/timolol 0.5% twice daily or dorzolamide 2%/timolol 0.5% twice daily as monotherapy (n = 101) or as adjunctive therapy to a prostaglandin analog (latanoprost, bimatoprost, or travoprost) (n = 79). At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine 0.2%/timolol 0.5% vs 6.7 (5.0) mmHg (26.1%) with dorzolamide 2%/timolol 0.5% (P < 0.040). The mean reduction from prostaglandin analog-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine 0.2%/timolol 0.5% vs 5.2 (3.7) mmHg (23.5%) with dorzolamide 2%/timolol 0.5% (P = 0.213). According to preliminary results from a small (n = 30), single-blind trial of cross-over, multicenter design and 3 month duration, the mean reduction in morning peak IOP from baseline at 3 months was 3.0 mmHg in the dorzolamide 2%/timolol 0.5% group versus 6.8 mmHg in the brimonidine 0.2%/timolol 0.5% group (P = 0.02).

**Versus brinzolamide 1%/timolol 0.5%**

In a 1-year, multicenter, randomized, double masked, active-controlled, parallel-group trial of brinzolamide 0.1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% with 437 patients, 220 were dosed brinzolamide 0.1%/timolol 0.5% and 217 received dorzolamide 2%/timolol 0.5%. IOP assessments were taken at 0800 and 1000 hours at week 2 and months 3 and 9, and at 0800, 1000, and 1600 hours at months 6 and 12. Brinzolamide 0.1%/timolol 0.5% produced IOP-lowering efficacy comparable to dorzolamide 2%/timolol 0.5%, with the upper 95% confidence limits for the differences between groups within +1.5 mmHg at all assessment times, including the month 6 primary efficacy time points, establishing noninferiority. The IOP reductions ranged from 7.2 to 9.2 mmHg for brinzolamide 0.1%/timolol 0.5% and from 7.4 to 8.9 mmHg for dorzolamide 2%/timolol 0.5%.

**Versus travoprost 0.004%/timolol 0.5%**

In a multicenter, double-masked, randomized clinical trial, 319 patients received either travoprost 0.004%/timolol 0.5% once daily in the morning (n = 157) or dorzolamide 2%/timolol 0.5% twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. Mean pooled diurnal IOP was significantly lower in the travoprost 0.004%/timolol 0.5% group (16.5 mmHg ± 0.23) than in the dorzolamide 2%/timolol 0.5% group (17.3 mmHg ± 0.23; P = 0.011). Moreover, travoprost 0.004%/timolol 0.5% combination produced superior mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide 2%/timolol 0.5% combination produced mean IOP reductions from baseline of 32.5% to 34.5%.

**Versus timolol 0.5% and pilocarpine 2%**

Dorzolamide 2%/timolol 0.5% was as effective as timolol 0.5% plus pilocarpine 2% in patients with glaucoma or ocular hypertension and was the preferred formulation. The dorzolamide/timolol has been compared with concomitant pilocarpine and timolol therapy in 2 trials (published as a single report). Two randomized trials with identical drug
administration and assessment protocols were performed; 1 in the US and 1 internationally (5 countries). Patients ≥18 years with baseline IOP of ≥22 mmHg after a 3-week run-in with timolol 0.5% twice daily were assigned to receive dorzolamide 2%/timolol 0.5% twice daily or timolol (0.5%) twice daily plus pilocarpine (2.0%) 4 times daily for 14 days. After a 7-day wash-out period, patients crossed over to receive the alternative therapy for a further 14 days. There were 97 patients in the US study and 93 in the international trial. The primary endpoints were patient preference and impact on daily life, and were assessed by a questionnaire administered by study physicians. IOP was also measured at baseline and on days 15, 22 and 36 at 2 and 4 hours after drug administration; only the IOP values from day 36 were published. After the 36-day study period there were no significant differences in IOP between the 2 treatment groups in either study.\(^5\) In the US study, the peak (2-hour) IOP in the dorzolamide/timolol group dropped from 23.7 mmHg at baseline to 19.8 mmHg at 36 days, and the corresponding values for the timolol plus pilocarpine concomitant therapy group were 23.5 mmHg at baseline and 20.1 mmHg at 36 days. In the international study, baseline peak IOP in the dorzolamide 2%/timolol 0.5% group was 24.4 mmHg dropping to 19.1 mmHg after 36 days, while peak IOP in the concomitant therapy group was 24.4 mmHg at baseline and 18.7 mmHg at the end of the trial. In both studies, patients preferred dorzolamide/timolol combination to concomitant therapy with timolol and pilocarpine by a ratio of approximately 4:1. The primary reason for this preference was the reduced frequency and severity of adverse effects although patients also reported that the combination therapy interfered less with daily life. Compliance was also improved and patients reported missing fewer doses with the twice daily combined therapy.

Kalzuny et al conducted a 6 week trial to compare the efficacy and safety of dorzolamide 2%/timolol 0.5% with fixed combination pilocarpine timolol, each given twice daily, in patients with POAG or ocular hypertensive patients. They found that both combinations were equally efficacious in IOP reduction\(^6\) (Table 3).

**Safety and tolerability**

Tolerability of a drug has been identified as a barrier to compliance.\(^7\) The adverse event profile of dorzolamide 2%/timolol 0.5% mirrors that of the individual components and consists primarily of ocular and local adverse events. The most common adverse events associated with dorzolamide (Trusopt\(^8\); Merck & Co., Inc., Whitehouse Station, NJ, USA) are ++ burning, stinging, and discomfort, and taste perversion (Trusopt\(^8\) prescribing information, Merck & Co., Inc., 2005; http://www.merck.com/product/usa/pi_circulars/t/trusopt/trusopt_pi.pdf); a similar safety profile is observed with the dorzolamide 2%/timolol 0.5% fixed combination (Cosopt\(^8\)) (Cosopt\(^8\) prescribing information, Merck & Co., Inc., 2006; http://www.merck.com/product/usa/pi_circulars/c/cosopt.html).

Dorzolamide 2%/timolol 0.5% twice daily was generally well tolerated in large (n = 177–492) trials of 3 to 6 months duration which evaluated this fixed combination in relation to the individual components, given either as monotherapy or concomitantly, or against other ocular hypotensive agents.\(^39–43,49,53–56,62\) Between 33% and 77% of patients receiving dorzolamide 2%/timolol 0.5% in these studies reported adverse events (regardless of cause);\(^39–45,53,54,65\) 10% to 68% reported drug-related adverse events;\(^42,43,53–56,67\) Transient and mild to moderate burning and/or stinging\(^19–41,45,49,53–56\) of the eye (5%–41%) was the most commonly reported ocular adverse event in majority of the trials. Dysgeusia\(^38–49,53–56\) (2%–38%) was the most common local adverse effect.

Recently, timolol 0.5% and brinzolamide 1% (Azopt\(^8\); Alcon Laboratories, Inc., Ft. Worth, TX, USA) have been formulated in a fixed combination (Azarga\(^8\); Alcon Laboratories, Inc., Ft. Worth, TX, USA). The most common side effects with brinzolamide 1% are blurred vision and taste perversion; fewer than 5% of patients report ocular discomfort associated with brinzolamide use in clinical trials (Azopt\(^8\) prescribing in formation, Alcon Laboratories, Inc. 2003; http://ecatalog.alcon.com/pi/Azopt_us_en.pdf). In a prospective, double-masked, randomized, active-controlled, crossover, multicenter study, 127 patients received 1 drop of brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in both eyes on consecutive days in random order. Ocular discomfort was rated 1 minute after instillation of each medication, and preference was noted on Day 2. Of the 106 subjects who expressed a drug preference, 79.2% preferred brinzolamide 1%/timolol 0.5% (P < 0.0001). Ocular discomfort scores were significantly higher with dorzolamide 2%/timolol 0.5% than brinzolamide 1%/timolol 0.5% (2.9 vs 1.4, respectively; P < 0.0001). Significantly more patients reported ocular pain and discomfort after dorzolamide 2%/timolol 0.5% instillation and transient blurred vision after brinzolamide 1%/timolol 0.5% instillation.\(^66\) Manni et al observed a similar overall safety profile between the two groups, but brinzolamide 1%/timolol 0.5% showed significantly less ocular irritation (2.7% vs 10.6%; P = 0.0009) than dorzolamide 2%/timolol 0.5%.\(^66\)
Teus et al have shown statistically significant difference in the amount of conjunctival hyperemia in travoprost 0.004%/timolol 0.5% group compared to dorzolamide 2%/timolol 0.5%, but it does not present any untoward safety issues.57

Long-term tolerability data are limited, although fixed combination was generally well tolerated for up to 1 year in a non-blind extension of one study.54

Conclusions

Efficacy and safety studies published till date show that dorzolamide with timolol is more efficacious than the individual components, and as effective as the components used concomitantly in controlled settings. Dorzolamide–timolol also has efficacy comparable to latanoprost 0.004%, pilocarpine 2%/timolol 0.5%, brinzolamide 0.1%/timolol 0.5% and unoprostone 0.15%/timolol 0.5% KLC. Dorzolamide-timolol is slightly more efficacious than latanoprost 0.005%/timolol 0.05% and brimonidine 0.2%/timolol 0.5%. In conclusion, dorzolamide–timolol combination has a good efficacy, safety and tolerability profile and hence an increased patient compliance.

Disclosures

The authors declare no conflicts of interest.

References

52. Day DG, Schacknow CJ, Wand M, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2003;135:138–143.
61. Kalzuny J, Szaflik J, Czechochowski-Janicka K. Timolol 0.5%/ dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand. 2003;81:349–354.
63. Konetas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/ timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004;18:1264–1269.
Combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

65. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. *J Glaucoma*. 2009;18:293–300.


68. Hatanaka M, Reis A, Sano ME, Susanna R Jr. Additive Intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. *J Glaucoma*. 2009 Sep 2. [Epub ahead of print].
